Argonaute Proteins Methods and Protocols
With the rapid proliferation of RNAi applications in basic and clinical sciences, the challenge has now become understanding how components of RNAi machinery function together in a regulated manner. Argonaute proteins are the central effectors of RN
- PDF / 7,601,180 Bytes
- 344 Pages / 504 x 720 pts Page_size
- 40 Downloads / 250 Views
in
Molecular Biology™
Series Editor John M. Walker School of Life Sciences University of Hertfordshire Hatfield, Hertfordshire, AL10 9AB, UK
For other titles published in this series, go to www.springer.com/series/7651
wwwwwwwwwwwwwwwwwwww
Argonaute Proteins Methods and Protocols Edited by
Tom C. Hobman Departments of Cell Biology and Medical Microbiology & Immunology, Li Ka Shing Institute of Virology, University of Alberta, Edmonton, AB, Canada
Thomas F. Duchaine Department of Biochemistry, Goodman Cancer Research Centre, Division of Experimental Medicine, McGill University, Montreal, QC, Canada
Editors Tom C. Hobman Departments of Cell Biology and Medical Microbiology & Immunology Li Ka Shing Institute of Virology University of Alberta Edmonton, AB, Canada [email protected]
Thomas F. Duchaine Department of Biochemistry, Goodman Cancer Research Centre, Division of Experimental Medicine, McGill University, Montreal, QC, Canada [email protected]
ISSN 1064-3745 e-ISSN 1940-6029 ISBN 978-1-61779-045-4 e-ISBN 978-1-61779-046-1 DOI 10.1007/978-1-61779-046-1 Library of Congress Control Number: 2011926589 © Springer Science+Business Media, LLC 2011 All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Humana Press, c/o Springer Science+Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden. The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights. Printed on acid-free paper Humana Press is part of Springer Science+Business Media (www.springer.com)
Preface The discovery of RNA interference (RNAi) is one of the most important biomedical findings of the past 25 years. First reported in 1998 by Fire et al. (Nature 391:806–11), the pace of advancement in this research area has been nothing less than breath taking. A mere 6 years after its formal discovery, RNAi-based therapeutics were already in clinical trials in humans … with promising results. Two years later, the two scientists who were credited with the discovery of this gene-silencing mechanism, Craig Mello and Andrew Fire, were awarded the Nobel Prize in physiology or medicine. The use of RNAi in academic and biotechnology research laboratories is now ubiquitous and, indeed, has revolutionized the study of eukaryotic gene function. Perhaps contributing to the wide spread incorporation of this technique into the toolbox of modern molecular biology is the fact that it offered a low-cost and fast-paced alternative to other reverse genetic technologies in a period that coincided with the dawn of the genomic
Data Loading...
